A biopharmaceutical is a medical product made using living cells or organisms rather than chemical synthesis. Unlike conventional drugs, which are typically small molecules assembled from chemical reactions in a lab, biopharmaceuticals are large, complex proteins produced by engineered living systems like bacteria, yeast, or animal cells. The global biopharmaceuticals market is valued at roughly $538 billion in 2025 and is one of the fastest-growing segments of the pharmaceutical industry.
How Biopharmaceuticals Differ From Conventional Drugs
The simplest way to understand biopharmaceuticals is to compare them to the pills most people are familiar with. A standard drug like ibuprofen or aspirin is a small, well-defined molecule made through chemical reactions. The manufacturing process is predictable, and every pill in a batch is essentially identical to every other pill. Analytical tests can fully characterize the final product down to its exact molecular structure.
Biopharmaceuticals work on a completely different scale. They are large molecules, often proteins containing hundreds of amino acids, with intricate three-dimensional shapes that determine how they function in the body. Because only living systems can produce them, and because living cells introduce natural variation, no two batches are perfectly identical. Each batch can have slight differences in surface sugars (a process called glycosylation) or in how the protein folds. This inherent variability is one of the defining characteristics of biologics and the reason they are so much harder to manufacture, regulate, and copy.
How They’re Made
Manufacturing a biopharmaceutical starts with genetically engineering a living cell to produce a specific therapeutic protein. The modified cells are placed in large steel vessels called bioreactors, where temperature, pH, oxygen supply, and nutrient levels are carefully controlled to keep the cells alive and productive. The entire environment must remain sterile, free of contaminating microorganisms that could ruin a batch or pose a safety risk to patients.
This process tends to yield relatively small quantities compared to chemical drug manufacturing. After the cells produce the target protein, an extensive purification process separates it from the cellular debris, growth media, and unwanted byproducts. The purification steps alone can account for a significant portion of total production costs. Even small changes in any step of the process can alter the final product, which is why the industry phrase “the process is the product” is so commonly used in biopharmaceutical manufacturing.
Major Types of Biopharmaceuticals
Biopharmaceuticals fall into several broad categories:
- Monoclonal antibodies: Lab-made proteins that mimic the immune system’s ability to target specific cells. They dominate the biopharmaceutical landscape, representing over 53% of all approvals in recent years. They’re used to treat cancers, autoimmune conditions like rheumatoid arthritis and lupus, and inflammatory diseases like Crohn’s disease.
- Recombinant hormones: Proteins like insulin and growth hormone produced by engineered cells. The first biopharmaceutical ever approved was Humulin, a synthetic human insulin that received FDA approval on October 28, 1982, replacing animal-derived insulin for diabetes treatment.
- Vaccines: Including newer nucleic acid-based vaccines like the mRNA COVID-19 vaccines, which use genetic instructions to teach cells to produce a target protein and trigger an immune response.
- Clotting factors and blood-related products: Used to treat hemophilia and other bleeding disorders.
- Interferons and interleukins: Proteins that regulate immune responses, used in conditions ranging from multiple sclerosis to certain cancers.
- Gene therapies: A newer category that delivers genetic material to correct or replace faulty genes. Sixteen gene-therapy-based products were approved in a recent four-year survey period alone.
Why Most Biologics Can’t Be Taken as Pills
If you’ve ever known someone on a biologic medication, you’ve probably noticed they receive it as an injection or infusion rather than swallowing a pill. There’s a straightforward biological reason for this. The digestive system is designed to break down proteins. Your stomach’s acidic environment, the enzymes in your gut, and the poor permeability of the intestinal lining all work against a large protein molecule trying to reach the bloodstream intact. These barriers make oral bioavailability extremely low for most biologics, so the drugs are delivered directly into the bloodstream or under the skin to bypass the digestive tract entirely.
This requirement for injection or infusion is one of the practical downsides of biopharmaceuticals for patients. Treatments often need to be administered in a clinic, or patients must learn to self-inject at home. Researchers are actively working on oral delivery strategies, but the gastrointestinal environment remains a formidable obstacle.
How Biologics Are Regulated
In the United States, biopharmaceuticals go through a different approval pathway than conventional drugs. Instead of a New Drug Application, manufacturers submit a Biologics License Application (BLA) to the FDA. The BLA requires detailed information about the applicant, the manufacturing process, preclinical studies, clinical trial data, and labeling. Because the manufacturing process so directly affects the final product, regulators scrutinize production methods far more intensely than they do for chemical drugs.
This regulatory framework also shapes how copies of biologics reach the market. Generic versions of conventional drugs simply need to prove they are bioequivalent to the original, meaning the active ingredient is chemically identical. Biosimilars, the biologic equivalent of generics, face a higher bar. Because living systems can’t produce a perfect molecular replica, biosimilar manufacturers must demonstrate their product is “highly similar” to the original with no clinically meaningful differences in safety, purity, or potency. This typically requires limited clinical trials, something generic drug makers don’t need to do.
Conditions Treated With Biopharmaceuticals
Biopharmaceuticals have transformed treatment for diseases that were once poorly managed. In oncology, monoclonal antibodies and immune checkpoint inhibitors are now standard treatments for Hodgkin lymphoma and cancers of the lung, liver, kidney, and bladder. These drugs work by helping the immune system recognize and attack cancer cells, or by blocking specific molecules that tumors use to grow.
Autoimmune diseases represent another major area. Biologics targeting specific immune pathways have become first-line treatments for rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis. For diabetes, recombinant insulin remains one of the most widely used biopharmaceuticals in the world, a direct descendant of that first 1982 approval. Recombinant clotting factors have dramatically improved quality of life for people with hemophilia, and recombinant growth hormones treat growth disorders in children and adults.
The scope continues to expand. Gene therapies are beginning to offer potential cures for conditions previously considered untreatable, including certain inherited blood disorders and retinal diseases. With the biopharmaceutical market projected to nearly quadruple by 2035, reaching close to $2 trillion, the number of conditions addressed by these products will only grow.